Skip to main content
IRTC
NASDAQ Industrial Applications And Services

iRhythm Beats on Q3 Revenue, Raises FY26 Guidance to $890-895M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$117.5
Mkt Cap
$4.291B
52W Low
$100.7
52W High
$192.47
52W Position info
17% above low
Off High info
39% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

IRTC sits 17% above its 52-week low of $100.7.

Summary

iRhythm posted Q3 revenue of $221.6M (up 14.9%) and adjusted EBITDA of $51.2M, then raised FY26 revenue guidance to $890-895M. A $49.8M litigation settlement charge drove the GAAP net loss to $29.9M.


Key Events · Earnings and Guidance · IRTC

  • Q3 Revenue Grows 14.9% to $221.6M

    Revenue rose from $192.9M a year ago on volume-led Zio Monitor demand; gross margin expanded 310 basis points to 74.2%.

  • FY26 Guidance Raised to $890-895M

    Adjusted EBITDA margin guidance lifted to 15.5-16.0%, inclusive of about $16M of expected VitalConnect revenue from the October 5 close through year-end.

  • Litigation Charge Drives $0.90 GAAP Loss

    A $49.8M Baxter patent litigation settlement charge pushed GAAP net loss to $29.9M; adjusted net income was $27.8M, or $0.82 per diluted share.

  • New $300M Revolver Closed November 3

    A new senior secured revolving credit facility adds liquidity on top of $560.7M in unrestricted cash, cash equivalents and marketable securities as of September 30, 2026.


Analysis · IRTC · Industrial Applications And Services

Revenue of $221.6M grew 14.9% and adjusted EBITDA more than doubled to $51.2M, but the GAAP picture is messier: a $49.8M Baxter patent litigation settlement charge pushed the net loss to $29.9M, or $0.90 per share. Management raised full-year revenue guidance to $890-895M and adjusted EBITDA margin to 15.5-16.0%, now including roughly $16M from VitalConnect, which closed October 5. The company also lined up a new $300M revolver on November 3, adding liquidity on top of $560.7M in cash and securities. The quarter's margin gain leans partly on a one-time $3.1M tariff refund, so the underlying run-rate is slightly less strong than the 74.2% gross margin suggests.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IRTC was trading at $117.50 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $100.70 to $192.47. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IRTC - Latest Insights

IRTC
Nov 17, 2026, 4:38 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $90.65
Real-time Price: $95.72 info
Change: +$5.07 (+6%) info
Market Cap: $3.168B info
IRTC
Nov 11, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $88.68
Real-time Price: $95.72 info
Change: +$7.04 (+8%) info
Market Cap: $3.168B info
IRTC
Nov 06, 2026, 1:07 PM EST
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $89.20
Real-time Price: $95.72 info
Change: +$6.52 (+7%) info
Market Cap: $3.168B info
IRTC
Nov 05, 2026, 5:20 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $110.00
Real-time Price: $95.72 info
Change: -$14.28 (-13%) info
Market Cap: $3.168B info
IRTC
Nov 05, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $130.19
Real-time Price: $95.72 info
Change: -$34.47 (-26%) info
Market Cap: $3.168B info